European Healthcare Analysts hold a conference call with management to discuss key CVRM growth drivers Farxiga, Breztri and Fasenra, including plans to progress Farxiga combinations into Phase III with baxdrostat, zibotentan and/or balcinrenone on September 15 at 9 am hosted by Jefferies. Webcast Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN:
- AstraZeneca (NASDAQ:AZN) Slides despite Solid Drug News
- Daiichi Sankyo, AstraZeneca present initial results from TROPION-Lung04 phase 1b
- AstraZeneca downgraded to Hold from Buy at Erste Group
- AstraZeneca says FDA issued a complete response letter for Ultomiris sBLA
- AstraZeneca’s Calquence approved in China for chronic lymphocytic leukaemia